Novartis AG NVS
145.46
2.75
1.93%
as of 25 Sep
- Market cap
- $264.3B
- P/E
- 21.8×
Follow NVS
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 30.37% | 34.98% | 30.84% | 32.64% |
+8 more TTM periods Free account |
|
| 11.27% | 12.39% | 13.12% | 13.65% | ||
ROIC |
13.14% | 13.97% | 16.10% | 16.85% | |
Return on Tangible Assets |
202.88% | 229.90% | 100.14% | 215.66% | |
Average Days of Receivables |
63.44 | 61.95 | 58.88 | 58.17 | |
Free Cash Flow per Share |
7.97 | 8.45 | 7.95 | 8.93 | |
Free Cash Flow |
15,177.00 | 16,128.00 | 15,421.00 | 17,207.00 | |
Capital Expenditures |
(3,216.00) | (3,047.00) | (3,723.00) | (3,866.00) | |
Piotroski F-Score |
4.00 | 4.00 | 7.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
19.02% | 21.08% | 20.88% | 24.90% | |
Accounts Receivable Turnover |
5.96 | 6.17 | 6.79 | 6.58 | |
Accounts Payable Turnover |
3.27 | 3.25 | 3.03 | 3.10 | |
Inventory Turnover |
2.29 | 2.30 | 2.28 | 2.17 | |
Average Days of Payables |
108.54 | 113.24 | 118.73 | 123.96 | |
Days of Inventory on Hand |
158.55 | 164.70 | 167.03 | 174.74 | |
Tax Rate |
(0.18) | (0.14) | (0.15) | (0.12) | |
Research and Development Expense of Revenue |
20.63% | 20.46% | 19.76% | 19.30% | |
Selling, General and Administrative Expense of Revenue |
23.16% | 23.56% | 23.38% | 23.61% | |
Share Based Compensation of Revenue |
2.01% | 2.01% | 1.93% | 1.90% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.44 | 1.42 | 1.37 | 1.46 | |
Depreciation/Fixed assets |
0.51 | 0.50 | 0.49 | 0.52 | |
Capex/Depreciation |
(0.59) | (0.58) | (0.71) | (0.72) | |
Revenue per Share |
29.76 | 29.64 | 29.23 | 29.27 | |
Operating CF per Share |
9.66 | 10.04 | 9.87 | 10.94 | |
Capex per Share |
(1.69) | (1.60) | (1.92) | (2.01) | |
Capex to Sales |
0.06 | 0.05 | 0.07 | 0.07 | |
Net Profit Margin |
22.50% | 23.92% | 24.67% | 25.53% |
Columns are period end dates